evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews · Heart

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 0 · 0%Moderate 3 · 60%High 1 · 20%

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Angiotensin receptor neprilysin inhibitors (ARNIs) vs usual care

Time to first hospitalisation for heart failure during · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in heart failure hospitalisation, first (RR) Range of compared with usual care (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs placebo or no treatment

Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor blockers (ARBs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (high certainty).

1 finding from 1 review

Beta‐blockers vs placebo or no treatment

Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction

It is very uncertain whether beta‐blockers changes heart failure hospitalisation (RR) compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction

Mineralocorticoid receptor antagonists (MRAs) probably leads to lower heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review